-
2023-506926-35-00
5
2021-09-24
Atherosclerotic cardiovascular disease, chronic kidney disease and sys
-
2024-515953-52-00
5
2020-07-24
Post-Essential Thrombocythaemia Myelofibrosis
-
2024-510976-19-00
5
2018-11-30
Patients with Unresectable Locally Advanced or Metastatic Urothelial C
-
2024-511057-22-00
5
2024-12-04
Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
-
2024-513104-34-00
4
2024-11-25
Major Depressive Disorder
-
2023-509197-35-00
5
2024-10-17
Thyroid Eye Disease (TED)
-
2023-507376-50-00
1
2024-09-27
Ulcerative Colitis
-
2023-506000-50-00
4
2024-09-26
Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-H
-
2023-507942-10-00
4
2024-07-31
Major depressive disorder
-
2023-509412-28-00
4
2024-07-26
Type 2 Diabetes
-
2024-511408-18-00
5
2024-07-15
Type 2 Diabetes inadequately controlled with dapagliflozin with or wit
-
2023-506565-57-00
5
2024-06-21
Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)
-
2023-506570-12-01
4
2024-06-13
Cognitive disorder
-
2023-506084-34-00
5
2024-04-12
Type 2 Diabetes
-
2023-503785-22-00
5
2024-03-25
complicated urinary tract infection (cUTI) or acute pyelonephritis (AP
-
2023-504678-39-00
4
2024-03-13
Heart Failure
-
2022-501946-31-00
5
2024-02-29
Functional Constipation
-
2022-501310-57-00
4
2024-02-05
Endometriosis related pain
-
2023-503333-22-00
5
2024-01-15
Moderate to severe controlled asthma according to Step 4 and Step 5 of
-
2022-501947-34-00
4
2023-12-05
Functional Constipation (FC)
-
2022-502854-16-00
4
2023-11-26
Asthma
-
2022-502208-64-00
4
2023-11-25
Asthma
-
2023-504339-41-00
5
2023-11-08
ESKD participants with history of secondary hyperparathyroidism (SHPT)
-
2022-502678-18-00
5
2023-11-07
Type 2 diabetes